JPJulio A. Panza

Julio A. Panza

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Julio A. Panza has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Carmine Cardillo

    Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Largo F. Vito 1, 00168 Rome, Italy

    4 shared publications
  • Umberto Campia

    National Heart, Lung, and Blood Institute, Bethesda, MD, USA

    4 shared publications
  • Ana Barac

    Inova Schar Heart and Vascular Institute and Inova Schar Cancer Institute, Inova Health System, Fairfax, VA

    2 shared publications
  • Melissa B. Bryant

    From the Cardiology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md. Dr Cardillo is presently at Università Cattolica del Sacro Cuore, Rome, Italy

    2 shared publications
  • Barbara V. Howard

    The MedStar Health Research Institute, Hyattsville, MD

    1 shared publication
  • Crescence M. Kilcoyne

    From the Cardiology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Md. Dr Cardillo is currently at Università Cattolica del Sacro Cuore, Rome, Italy

    1 shared publication

Latest Publications

  • Inducible Myocardial Ischemia and Outcomes in Patients With Coronary Artery Disease and Left Ventricular Dysfunction

    by Julio A. Panza, Thomas A. Holly, Federico M. Asch, Lilin She, Patricia A. Pellikka, Eric J. Velazquez, Kerry L. Lee, Salvador Borges-Neto, Pedro S. Farsky, Robert H. Jones, et al.


  • Open Access

    Markers of Inflammation, Metabolic Risk Factors, and Incident Heart Failure in American Indians: The Strong Heart Study

    by Ana Barac, Hong Wang, Nawar M. Shara, Giovanni de Simone, Elizabeth A. Carter, Jason G. Umans, Lyle G. Best, Jeunliang Yeh, Damon B. Dixon, Richard B. Devereux, et al.

    Inflammation may play a role in increased risk of heart failure (HF) that is associated with obesity, metabolic syndrome (MS), and diabetes. This study investigated associations between inflammatory markers, MS, and incident HF in a population with a high prevalence of diabetes, obesity, and MS. The cohort consisted of 3098 American Indians without prevalent cardiovascular disease who had C‐reactive protein (CRP) and fibrinogen measured at the Strong Heart Study phase II examination. Independent associations between inflammatory markers, MS, and HF were analyzed by Cox hazard models. During a mean follow‐up of 11 years, 218 participants developed HF. After the adjustment for cardiovascular risk factors, fibrinogen, (hazard ratio [HR], 1.36; 95% confidence interval [CI], 1.15–1.59) but not CRP (HR, 1.25; 95% CI, 0.97–1.32) remained a significant HF predictor. In individuals without diabetes, concomitant presence of MS and elevated CRP or fibrinogen increased HF risk (for MS and CRP: HR, 2.02; 95% CI, 0.95–4.31; for CRP and fibrinogen: HR, 1.75; 95% CI, 0.83–3.72). In a population with a high prevalence of obesity, MS, and diabetes, elevated CRP and fibrinogen increased HF risk. These associations are attenuated by the adjustments for conventional risk factors suggesting that inflammation acts in concert with metabolic and clinical risk factors in increasing HF risk.


  • Open Access

    Coronary atherosclerosis: extending to the microcirculation?

    by Julio A. Panza

    This editorial refers to ‘Coronary microcirculatory vasodilator function in relation to risk factors among patients without obstructive coronary disease and low to intermediate Framingham risk score’†, by R. Rubinshtein et al. on page 936


  • Book Review High-Risk Atherosclerotic Plaques: Mechanisms, Imaging, Models, and Therapy Edited by Levon Michael Khachigian. 208 pp., illustrated. Boca Raton, Fla., CRC Press, 2005. $99.95. 0-8493-3028-9

    by Julio A. Panza

    The fact that cardiovascular disease, for the most part due to atherosclerosis, is the principal killer in Western societies is well known. However, how and why atherosclerotic plaques that develop over many decades rupture in an often unheralded manner — triggering the clinical presentation of an acute coronary syndrome — is still puzzling. High-Risk Atherosclerotic Plaques addresses this problem in a wide-ranging manner with chapters that follow a rational sequence, unfolding the processes involved in plaque rupture, reviewing the efforts to develop animal models of the phenomenon, explaining the different methods devised to identify and study vulnerable plaques, and summarizing the current and future strategies for treatment. This book is best suited for readers familiar with basic concepts about the development and clinical presentation of atherosclerosis who seek a detailed review of the mechanisms leading to the presentation of acute coronary syndromes.

  • Open Access

    Ethnic Differences in the Vasoconstrictor Activity of Endogenous Endothelin-1 in Hypertensive Patients

    by Umberto Campia, Carmine Cardillo, Julio A. Panza

    Background— The pathogenesis of essential hypertension in blacks may differ from that in whites. In particular, black patients usually present with a salt-sensitive, low-renin form, which in animal models is associated with enhanced activity of endothelin-1 (ET-1). This study aimed to assess whether ethnic differences exist in the vascular activity of ET-1 in normotensive and hypertensive blacks and whites. Methods and Results— Forearm blood flow (FBF) responses to intraarterial infusion of an ET A receptor blocker (BQ-123) were analyzed by plethysmography in 37 normotensive patients and 27 hypertensive patients according to race. BQ-123 did not affect FBF in normotensive subjects ( P =0.30), whereas it produced significant vasodilation in hypertensive subjects ( P P =0.85). In contrast, in hypertensive patients, the vasodilator effect of ET A receptor blockade was significantly higher in blacks (n =13) than in whites (n =14) ( P =0.01). To rule out differences in smooth muscle reactivity, the effects of race on FBF responses to exogenous ET-1 were analyzed in the hypertensive subgroups. Endothelin-1 induced a significant vasoconstriction in both white (n =7) and black patients (n =5) (both P P =0.46). In 8 black hypertensives, the response to selective ET A blockade was not modified by nonselective blockade of ET-1 receptors by co-infusion of BQ-123 and BQ-788 ( P =0.66). Conclusions— Hypertensive blacks have enhanced ET A -dependent vasoconstrictor tone, probably related to increased production of ET-1. Given the negative vascular effects of ET-1, this abnormality may contribute to the pathogenesis of hypertension and its complications in black patients.


  • Enhanced Vascular Activity of Endogenous Endothelin-1 in Obese Hypertensive Patients

    by Carmine Cardillo, Umberto Campia, Micaela Iantorno, Julio A. Panza

    Hypertensive patients have increased endothelin-1–dependent vasoconstrictor tone. This abnormality, however, might not be uniformly present in all forms of hypertension, as suggested by experimental studies showing that endothelin-1 activity is enhanced predominantly in low-renin, high-volume models and in insulin-resistant states. Because hypertension in obesity is commonly associated with both expanded plasma volume and insulin resistance, this study sought to determine whether increased body mass index (BMI) in hypertensive patients relates to activation of the endothelin-1 system. Forearm blood flow (FBF) responses (plethysmography) to intra-arterial infusion of an ET A receptor blocker (BQ-123) were analyzed in hypertensive patients and normotensive control subjects according to BMI. The vasodilator response to BQ-123 was significantly higher in hypertensive patients than in control subjects ( P 2 ; P 2 ; P =0.04) but not in lean (BMI 2 ; P =0.83) hypertensive patients. In contrast, no significant change in FBF was observed during BQ-123 either in obese ( P =0.53), overweight ( P =0.76), or lean ( P =0.93) normotensive subjects. Moreover, a significant correlation between BMI and the vasodilator response to ET A blockade was observed in hypertensive subjects ( R =0.53; P =0.005) but not in control subjects ( R =0.11; P =0.58). In human hypertension, increased BMI is associated with enhanced ET A -dependent vasoconstrictor activity, suggesting that this abnormality may play a role in the pathophysiology of obesity-related hypertension and that targeting the endothelin-1 system may be useful in the treatment of these patients.


  • Increased Activity of Endogenous Endothelin in Patients With Type II Diabetes Mellitus

    by Carmine Cardillo, Umberto Campia, Melissa B. Bryant, Julio A. Panza

    Background— Endothelial dysfunction may contribute to the risk of premature atherosclerosis in patients with diabetes. Endothelin (ET-1) may be involved in this process by activating smooth muscle cell mitogenesis and leukocyte adhesion. We sought to assess the activity of endogenous ET-1 in a group of patients with type II diabetes mellitus with the use of antagonists of ET-1 receptors. Methods and Results— Forearm blood flow (FBF) responses (strain gauge plethysmography) to intraarterial infusion of a selective blocker of ET A receptors (BQ-123) and, on a different occasion, to ET-1, were measured in 15 patients with diabetes and 12 healthy controls. In addition, 5 patients with diabetes received coinfusion of BQ-123 and BQ-788 (a selective blocker of ET B receptors). In normal subjects, BQ-123 did not significantly modify FBF from baseline ( P =0.16). In contrast, BQ-123 administration resulted in a significant vasodilator response in patients with diabetes ( P P =0.001), whereas the vasoconstrictor response to norepinephrine was similar in the 2 groups ( P =0.78). In patients with diabetes, the vasodilator response to selective ET A blockade was not significantly modified by nonselective blockade of ET-1 receptors obtained by coinfusion of BQ-123 and BQ-788. Conclusions— The activity of endogenous ET-1 on ET A receptors is enhanced in the resistance vessels of patients with diabetes, whereas their sensitivity to exogenous ET-1 is blunted. This abnormality may participate in the pathophysiology of vascular complications associated with diabetes.


  • Improved Endothelium-Dependent Vasodilation After Blockade of Endothelin Receptors in Patients With Essential Hypertension

    by Carmine Cardillo, Umberto Campia, Crescence M. Kilcoyne, Melissa B. Bryant, Julio A. Panza

    Background — Hypertensive patients have both impaired endothelium-dependent vasodilation and increased activity of the endothelin (ET-1) system, which participate in their increased vascular tone and may predispose them to atherosclerosis. This study investigated the contribution of increased ET-1 activity to the impaired endothelium-dependent vasodilator function of hypertensive patients. Methods and Results — Forearm blood flow (FBF) responses to intraarterial infusion of acetylcholine (ACh; 7.5, 15, and 30 μg/min) and sodium nitroprusside (SNP; 0.8,1.6, and 3.2 μg/min) were assessed by strain-gauge plethysmography before and after nonselective blockade of ET A and ET B receptors by combined infusion of BQ-123 (ET A blocker; 100 nmol/min) and BQ-788 (ET B blocker; 50 nmol/min). During saline administration, the vasodilator response to ACh was significantly blunted in hypertensive patients compared with controls ( P P =0.74). Blockade of ET-1 receptors resulted in a significant increase in FBF from baseline in hypertensive patients ( P P =0.15). In hypertensive patients, a combined ET A/B blockade resulted in a significant potentiation of the vasodilator response to ACh compared with saline ( P =0.01), whereas the response to SNP was unchanged ( P =0.44). In contrast, the response to ACh was not significantly modified by ET-1 receptor antagonism in healthy subjects ( P =0.14 compared with saline). Conclusions — These findings indicate that blockade of ET-1 receptors improves endothelium-dependent vasodilator function in hypertensive patients, thereby suggesting that an increased ET-1 activity may play a role in the pathophysiology of this abnormality.